Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew I Milowsky

Showing results (51-60 of 205) with videos related to

Pageof 21
Sort By:
Frontiers in Oncology|May 7, 2024
Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancerBlaine Brower, Asia McCoy, Hiba Ahmad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancerNeil H Bander, Matthew I Milowsky, David M Nanus, et al.
Cancer|February 14, 2009
Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000Kevin A David, Katherine Mallin, Matthew I Milowsky, et al.
Seminars in Oncology|October 23, 2003
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigenNeil H Bander, David M Nanus, Matthew I Milowsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2004
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancerMatthew I Milowsky, David M Nanus, Lale Kostakoglu, et al.
Clinical Genitourinary Cancer|April 3, 2023
Dose Intensity in Real-World Patients With Metastatic Renal Cell Carcinoma Taking Vascular Endothelial Growth Factor Receptor Tyrosine Kinase InhibitorsHartlee Johnston, Allison M Deal, Katherine P Morgan, et al.
Case Reports in Pathology|September 10, 2015
Metachronous Bilateral Testicular Leydig-Like Tumors Leading to the Diagnosis of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)Josip Vukina, David D Chism, Julie L Sharpless, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancerAndrea B Apolo, Jamie Riches, Heiko Schöder, et al.
Kidney Cancer Journal : Official Journal of the Kidney Cancer Association|January 7, 2026
Current perspective on the impact of endogenous retroviruses in clear cell renal cell carcinomaKathryn H Gessner, Mi Zhou, Tracy L Rose, et al.
Urologic Oncology|November 4, 2015
Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigenAaron D Falchook, Neil E Martin, Ramsankar Basak, et al.
Pageof 21

Showing results (51-60 of 205) with videos related to

Sort By:
Pageof 21
Frontiers in Oncology|May 7, 2024
Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancerBlaine Brower, Asia McCoy, Hiba Ahmad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancerNeil H Bander, Matthew I Milowsky, David M Nanus, et al.
Cancer|February 14, 2009
Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000Kevin A David, Katherine Mallin, Matthew I Milowsky, et al.
Seminars in Oncology|October 23, 2003
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigenNeil H Bander, David M Nanus, Matthew I Milowsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2004
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancerMatthew I Milowsky, David M Nanus, Lale Kostakoglu, et al.
Clinical Genitourinary Cancer|April 3, 2023
Dose Intensity in Real-World Patients With Metastatic Renal Cell Carcinoma Taking Vascular Endothelial Growth Factor Receptor Tyrosine Kinase InhibitorsHartlee Johnston, Allison M Deal, Katherine P Morgan, et al.
Case Reports in Pathology|September 10, 2015
Metachronous Bilateral Testicular Leydig-Like Tumors Leading to the Diagnosis of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)Josip Vukina, David D Chism, Julie L Sharpless, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancerAndrea B Apolo, Jamie Riches, Heiko Schöder, et al.
Kidney Cancer Journal : Official Journal of the Kidney Cancer Association|January 7, 2026
Current perspective on the impact of endogenous retroviruses in clear cell renal cell carcinomaKathryn H Gessner, Mi Zhou, Tracy L Rose, et al.
Urologic Oncology|November 4, 2015
Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigenAaron D Falchook, Neil E Martin, Ramsankar Basak, et al.
Pageof 21